MX384716B - Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia. - Google Patents

Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia.

Info

Publication number
MX384716B
MX384716B MX2016009850A MX2016009850A MX384716B MX 384716 B MX384716 B MX 384716B MX 2016009850 A MX2016009850 A MX 2016009850A MX 2016009850 A MX2016009850 A MX 2016009850A MX 384716 B MX384716 B MX 384716B
Authority
MX
Mexico
Prior art keywords
polypeptide
treatment
immunodeficiency
microbial infections
subject
Prior art date
Application number
MX2016009850A
Other languages
English (en)
Spanish (es)
Other versions
MX2016009850A (es
Inventor
Mats Peter Clarsund
Ulf Thomas Blom
Original Assignee
Enzymatica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201401480A external-priority patent/GB201401480D0/en
Priority claimed from GBGB1405784.8A external-priority patent/GB201405784D0/en
Application filed by Enzymatica Ab filed Critical Enzymatica Ab
Publication of MX2016009850A publication Critical patent/MX2016009850A/es
Publication of MX384716B publication Critical patent/MX384716B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2016009850A 2014-01-29 2015-01-29 Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia. MX384716B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201401480A GB201401480D0 (en) 2014-01-29 2014-01-29 Novel treatments
GBGB1405784.8A GB201405784D0 (en) 2014-03-31 2014-03-31 Novel methods, polypeptides and uses thereof
PCT/GB2015/050212 WO2015114343A1 (en) 2014-01-29 2015-01-29 Novel treatments

Publications (2)

Publication Number Publication Date
MX2016009850A MX2016009850A (es) 2017-02-17
MX384716B true MX384716B (es) 2025-03-14

Family

ID=52630400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009850A MX384716B (es) 2014-01-29 2015-01-29 Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia.

Country Status (14)

Country Link
US (2) US20160339087A1 (2)
EP (2) EP3932420A1 (2)
JP (1) JP6718375B2 (2)
KR (1) KR20160108560A (2)
CN (1) CN106232810A (2)
AU (1) AU2015212554B2 (2)
BR (1) BR112016017478A2 (2)
DK (1) DK3099317T3 (2)
ES (1) ES2890555T3 (2)
MX (1) MX384716B (2)
PL (1) PL3099317T3 (2)
PT (1) PT3099317T (2)
RU (1) RU2732378C2 (2)
WO (1) WO2015114343A1 (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405784D0 (en) * 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
EP3120866A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
GB201701315D0 (en) * 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
KR20250160224A (ko) * 2018-10-11 2025-11-11 모멘타 파머슈티컬스 인코포레이티드 고도로 실릴화된 IgG 조성물에 의한 치료
WO2020175936A1 (ko) 2019-02-28 2020-09-03 단디바이오사이언스 주식회사 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물
KR102368983B1 (ko) * 2019-02-28 2022-03-03 단디바이오사이언스 주식회사 항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물
CN115666512A (zh) * 2020-05-13 2023-01-31 智密科技公司 用于治疗微生物感染的蛋白酶制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
RU2264824C2 (ru) * 1999-06-18 2005-11-27 Йон Браги БЬЯРНАСОН Сериновые протеиназы рыб и их фармацевтическое и косметическое применение
NZ523900A (en) * 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
US9511125B2 (en) * 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
WO2012104099A1 (en) * 2011-02-04 2012-08-09 Glucometrix Ag Process for the production of recombinant trypsin

Also Published As

Publication number Publication date
EP3099317B1 (en) 2021-08-04
DK3099317T3 (en) 2021-08-23
ES2890555T3 (es) 2022-01-20
EP3099317A1 (en) 2016-12-07
CN106232810A (zh) 2016-12-14
PT3099317T (pt) 2021-11-12
RU2732378C2 (ru) 2020-09-16
EP3932420A1 (en) 2022-01-05
US20160339087A1 (en) 2016-11-24
AU2015212554B2 (en) 2020-09-03
AU2015212554A1 (en) 2016-08-18
BR112016017478A2 (pt) 2017-10-10
JP2017505624A (ja) 2017-02-23
US20190343932A1 (en) 2019-11-14
WO2015114343A1 (en) 2015-08-06
PL3099317T3 (pl) 2022-01-03
RU2016135003A3 (2) 2019-02-14
RU2016135003A (ru) 2018-03-07
JP6718375B2 (ja) 2020-07-08
MX2016009850A (es) 2017-02-17
KR20160108560A (ko) 2016-09-19

Similar Documents

Publication Publication Date Title
MX384716B (es) Polipéptido con actividad proteasa para su uso en el tratamiento de infecciones microbianas en un sujeto con una inmunodeficiencia.
DOP2017000156A (es) Derivados de glucagón con estabilidad mejorada
CL2016002971A1 (es) Combinación.
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
CO2017008148A2 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
MX2017014204A (es) Formulaciones de tpp1 y metodos para tratar la enfemedad de cln2.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
MX2019009860A (es) Uso mejorado de neurotoxina botulinica en el tratamiento de sialorrea.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CO2020014399A2 (es) Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
MX390488B (es) Composicion farmaceutica de clorhidrato de amantadina-loratadina-paracetamol para integrar una capsula, para el tratamiento de refriados entre otras alopatias.
AR104200A1 (es) Carboximetilcisteina para tratamiento tópico de estrías
AR122764A2 (es) Formulación de un polipéptido del factor viii, kit farmacéutico, método
AR104549A1 (es) Formulaciones de tripeptidil peptidasa 1 (tpp1) y métodos de tratamiento de una lipofuscinosis ceroide neuronal (cln2)
UA126148U (uk) Спосіб лікування періімплантного мукозиту
EA201991866A1 (ru) Комбинированная терапия